NAS:COEP (USA)
Â
Ordinary Shares
$
16.4
+0.24 (+1.52%)
10:08 PM EST
Business Description
Coeptis Therapeutics Holdings Inc
NAICS : 541714
SIC : 2836
ISIN : US19207A2078
Share Class Description:
COEP: Ordinary SharesTotal Employee Number:
6Description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.61 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 17.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 63.6 | |||||
3-Year EPS without NRI Growth Rate | 59.9 | |||||
3-Year FCF Growth Rate | 27.9 | |||||
3-Year Book Growth Rate | -19.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.67 | |||||
9-Day RSI | 77.62 | |||||
14-Day RSI | 72.1 | |||||
3-1 Month Momentum % | -25.71 | |||||
6-1 Month Momentum % | -30.67 | |||||
12-1 Month Momentum % | -16.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.16 | |||||
Quick Ratio | 4.16 | |||||
Cash Ratio | 3.59 | |||||
Days Sales Outstanding | 15.13 | |||||
Days Payable | 2065.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.5 | |||||
Shareholder Yield % | -6.52 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 86.79 | |||||
Operating Margin % | -956.93 | |||||
Net Margin % | -800.44 | |||||
EBITDA Margin % | -763.83 | |||||
FCF Margin % | -631.18 | |||||
OCF Margin % | -631.18 | |||||
ROE % | -136.77 | |||||
ROA % | -84.07 | |||||
ROIC % | -120.4 | |||||
3-Year ROIIC % | 560.2 | |||||
ROC (Joel Greenblatt) % | -23550.61 | |||||
ROCE % | -127.08 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 57.54 | |||||
PB Ratio | 6.95 | |||||
Price-to-Tangible-Book | 7.45 | |||||
EV-to-EBIT | -8.29 | |||||
EV-to-Forward-EBIT | -2.93 | |||||
EV-to-EBITDA | -9.27 | |||||
EV-to-Forward-EBITDA | -2.93 | |||||
EV-to-Revenue | 70.79 | |||||
EV-to-FCF | -11.22 | |||||
| Price-to-Net-Current-Asset-Value | 19.76 | |||||
| Price-to-Net-Cash | 25.23 | |||||
Earnings Yield (Greenblatt) % | -12.06 | |||||
FCF Yield % | -8.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COEP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coeptis Therapeutics Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.363 | ||
| EPS (TTM) ($) | -2.764 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.6 | ||
| Volatility % | 71.44 | ||
| 14-Day RSI | 72.1 | ||
| 14-Day ATR ($) | 1.091451 | ||
| 20-Day SMA ($) | 12.876 | ||
| 12-1 Month Momentum % | -16.6 | ||
| 52-Week Range ($) | 6.26 - 21.41 | ||
| Shares Outstanding (Mil) | 6.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coeptis Therapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coeptis Therapeutics Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 43 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 16.21 (+6.71%) | ||
| General meeting for 2025 | 2026-04-27 | 16.21 (+6.71%) | ||
| Annual report for 2025 | 2026-03-19 | 11.11 (-11.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 14.15 (-5.54%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 10.86 (-3.04%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 9.85 (-1.99%) | ||
| Annual report for 2024 | 2025-03-28 | 9.31 (-2.31%) | ||
| 0.05:1 Stock Split | 2024-12-31 | 3.10 (-3.13%) |
Show
Entries
Coeptis Therapeutics Holdings Inc Frequently Asked Questions
What is Coeptis Therapeutics Holdings Inc(COEP)'s stock price today?
The current price of COEP is $16.40. The 52 week high of COEP is $21.41 and 52 week low is $6.26.
When is next earnings date of Coeptis Therapeutics Holdings Inc(COEP)?
The next earnings date of Coeptis Therapeutics Holdings Inc(COEP) is 2026-08-14 Est..
Does Coeptis Therapeutics Holdings Inc(COEP) pay dividends? If so, how much?
Coeptis Therapeutics Holdings Inc(COEP) does not pay dividend.
Guru Commentaries on NAS:COEP
No articles.
Press Release
Articles on Coeptis Therapeutics Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers